Needham analyst Joseph Stringer has maintained their neutral stance on MRNA stock, giving a Hold rating today.
Joseph Stringer has given his Hold rating due to a combination of factors related to Moderna’s current financial and strategic outlook. The company’s first-quarter revenue for 2025 was in line with expectations, and while the earnings per share exceeded estimates, the overall financial performance suggests cautious optimism. Moderna’s reiterated revenue guidance for 2025 indicates a reliance on the latter half of the year, reflecting the seasonal nature of its respiratory vaccine business.
Additionally, significant operating expense reductions are planned for the coming years, aiming for cash breakeven by 2028. Despite the promising potential in Moderna’s oncology pipeline, which could drive value in the future, the current competitive pressures and commercial challenges in the respiratory vaccine sector temper immediate growth expectations. As such, the Hold rating reflects a balanced view of potential opportunities and existing challenges.
Stringer covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Alnylam Pharma, and Ionis Pharmaceuticals. According to TipRanks, Stringer has an average return of -5.7% and a 35.00% success rate on recommended stocks.
In another report released today, TD Cowen also maintained a Hold rating on the stock with a $30.00 price target.